Delaware Chapter of the American College of Cardiology

Join us for the ACC Delaware Chapter Meeting: ACC by the Sea for engaging live education sessions from local, regional, and national experts with Q&A real-time. The educational meeting includes topics of cardio obstetrics, lipids, amyloid, etc., and a chapter update from our Governor Dr. Vinay Hosmane. Participation in this event will earn CME/CNE/and MOC. We look forward to seeing you (IN-PERSON) October 25 – 27, 2024!

For more Information and Register: Delaware ACC By the Sea: 2024 Chapter Meeting

Delaware Chapter of the American College of Cardiology

Our purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments.

ACC Live Courses

For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

Latest in Cardiology from ACC.org

Revascularization for Ischemic Ventricular Dysfunction
The goal of the REVIVED-BCIS2 trial was to evaluate percutaneous coronary intervention (PCI) plus optimal medical therapy compared with optimal medical therapy alone among individuals with left ventricular ejection fraction (LVEF) ≤35% and extensive coronary artery disease (CAD).
CV Sports Chat: Dilated Aortas in Athletes
"CV Sports Chat"â€¯is an interview series including expert discussions relative to sports and exercise cardiology and the health care management of athletes.
Temporary Mechanical Circulatory Support in Infarct-Related CS
What is the effect of early routine active percutaneous mechanical circulatory support (MCS) versus control treatment on 6-month all-cause mortality in patients with acute myocardial infarction-related cardiogenic shock (AMICS)?
Anticoagulation in Device-Detected AF With or Without Vascular Disease
What is the impact of concomitant vascular disease on the benefits and risks of anticoagulation for patients with device-detected atrial fibrillation (DDAF)?
Semaglutide in HFpEF: Pooled Analysis of Four Randomized Trials
Does semaglutide reduce risk for adverse cardiovascular (CV) events in patients with heart failure with preserved ejection fraction (HFpEF)?